9:15 am Sustainable Treatments to Reverse MASH & Obesity-Linked Comorbidities
- Quelling hepatic injury through strategic inflammatory modulation to dampen the damaging inflammatory cascade within the liver to benefit the long-term trajectory of the disease
- Understanding the biology of targeting chemokine receptors (e.g., CCR2/CCR5 inhibition) to limit the recruitment of inflammatory cells to the liver to introduce a new method of treating MASH
- Investigating the potential of inhibiting apoptosis pathways (e.g., ASK1 inhibition) to preserve hepatocytes to reduce liver damage driven by inflammation